Moffitt-USF Head Toward First Human Trials of Anti-cancer Drug that Targets Protein AKT
Posted on: Friday, 24 June 2005, 14:45 CDT
Tampa, FL (June 24, 2005)-H. Lee Moffitt Cancer Center & Research Institute, working in partnership with the University of South Florida (USF), has discovered a new use for an old, previously discredited anti-cancer drug that could add another weapon in the arsenal against several cancers, including tumors of the breast, ovary, colon, skin and prostate.
The compound, tricirbine, was tested at various cancer centers from 1982 to 1996 and found to inhibit some cancers, but researchers failed to determine why. The Moffitt-USF team discovered that tricirbine works only against tumors in which the cancer-causing Akt protein is abundant and/or abnormally active.
"These tumors are addicted to hyperactive Akt and cannot survive without it," explains Saïd Sebti, Ph.D., Moffitt's Manuel and Adeline Garcia Professor, Leader of the Drug Discovery Program and Associate Director of Moffitt Research Institute. "What we discovered is a tailored therapy for tumors with a specific molecular signature."
Resurrecting tricirbine may be promising for patients with ovarian cancer, for instance, because "40 percent of women with ovarian cancer have tumors with high levels of active Akt," according to Sebti.
"To our knowledge, this is the first Akt inhibitor headed toward clinical trials," said Jin Cheng, MD, PhD, USF Professor of Pathology and Interdisciplinary Oncology.
Cheng and Sebti's study results were published in the journal Cancer Research.
VioQuest Pharmaceuticals Inc. (VQPH) of New Jersey is acquiring the licensing rights to the compound from USF through its merger with Greenwich Therapeutics Inc. and is planning clinical trials with Moffitt. The trials are expected to start within six to eight months. Patients will be selected for the trials based on whether their tumors have hyperactive Akt, which can be determined by a simple slide-stain test of tumor tissue.
Because tricirbine has previously been investigated in humans, the hypothesis-driven clinical trials planned at Moffitt can move directly into a PhaseI/II trial.
With the step-up of functional-genomics research at Moffitt and around the country, the advent of "customized medicine" has been heralded in headlines and at medical conferences. The clinical trial of this Akt-inhibitor is a concrete step toward that reality. Sebti says, "The beauty of this trial is that it's molecular therapy, based on the blueprint of the tumor cell."
On the Internet:
University of South Florida Health Sciences Center
Related Articles
- First-of-its-Kind Collaboration Among Advocacy Groups Provides Lung Cancer Patients Personalized Information About Clinical Trials
- Moffitt Cancer Center Chief Participates in Clinical Trial Resulting in FDA Approval of New Label for Myelodysplastic Therapy VIDAZA
- Epigenomics AG Successfully Validates Optimized Blood-Based Colorectal Cancer Assay in Two Independent Clinical Studies
- Hollis-Eden Pharmaceuticals Announces Filing of IND With APOPTONE(TM) in Hormone Sensitive Cancers to Commence Phase I/II Clinical Trial in Late-Stage Prostate Cancer
- First Prostate Cancer Patients Treated in a Phase I Clinical Trial As Part of a Collaboration Between Generex Biotechnology and the Saint Savas Cancer Hospital
- View Scientific Rationale for Novel Therapeutics in Lung Cancer, And the Results of Clinical Trials to Date Inside 'Triple Analysis: Non Small Cell Lung Cancer, Protein Kinase Inhibitors & Anti-Angiogenic Agents'
- Glaxo to put 4 new cancer drugs into final trials
- Glaxo sees 4 cancer drugs in final trials in 2006
- Columbus, Ga., Cancer Center is Popular for Clinical Trials
- Introgen's Novel P53 Cancer Vaccine Sensitizes Tumors to Platinum and Taxane Chemotherapies
 |
 |
User Comments (0)
RSS Feeds